

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 August 2002 (29.08.2002)

PCT

(10) International Publication Number
WO 02/066640 A2

(51) International Patent Classification⁷: C12N 15/12,
C07K 14/47

F. [US/US]; 755 Pacific Surf Drive, Solana Beach, CA
92075 (US). DREIER, Birgit [DE/CH]; Loowiesenstrasse
15, CH-8106 Adlikon (CH).

(21) International Application Number: PCT/EP02/01862

(22) International Filing Date: 21 February 2002 (21.02.2002)

(74) Agent: BECKER, Konrad; Novartis AG, Corporate
Intellectual Property, Patent & Trademark Department,
CH-4002 Basel (CH).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/791,106 21 February 2001 (21.02.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH,
PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA,
US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except AT, US*): NO-
VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel
(CH).

(84) Designated States (*regional*): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

(71) Applicant (*for AT only*): NOVARTIS-ERFINDUNGEN
VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT];
Brunner Strasse 59, A-1230 Vienna (AT).

Published:

— without international search report and to be republished
upon receipt of that report

(71) Applicant (*for all designated States except US*): THE
SCRIPPS RESEARCH INSTITUTE [US/US]; 10550
North Torrey Pines Road, La Jolla, CA 92037 (US).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BARBAS, Carlos,



WO 02/066640 A2

(54) Title: ZINC FINGER BINDING DOMAINS FOR NUCLEOTIDE SEQUENCE ANN

(57) Abstract: Polypeptides that contain from 2 to 12 zinc finger-nucleotide binding regions that bind to nucleotide sequences of the formula (ANN)₂₋₁₂ are provided. Polynucleotides that encode such polypeptides and methods of regulating gene expression with such polypeptides and polynucleotides are also provided.

ZINC FINGER BINDING DOMAINS FOR NUCLEOTIDE SEQUENCE ANN

Technical Field of the Invention

The field of this invention is zinc finger protein binding to target nucleotides. More particularly, the present invention pertains to amino acid residue sequences within the α -helical domain of zinc fingers that specifically bind to target nucleotides of the formula 5'-(ANN)-3'.

Background of the Invention

The construction of artificial transcription factors has been of great interest in the past years. Gene expression can be specifically regulated by polydactyl zinc finger proteins fused to regulatory domains

Zinc finger domains of the Cys₂-His₂ family have been most promising for the construction of artificial transcription factors due to their modular structure. Each domain consists of approximately 30 amino acids and folds into a $\beta\beta\alpha$ structure stabilized by hydrophobic interactions and chelation of a zinc ion by the conserved Cys₂-His₂ residues. To date, the best characterized protein of this family of zinc finger proteins is the mouse transcription factor Zif 268 [Pavletich et al., (1991) *Science* 252(5007), 809-817; Elrod-Erickson et al., (1996) *Structure* 4(10), 1171-1180]. The analysis of the Zif 268/DNA complex suggested that DNA binding is predominantly achieved by the interaction of amino acid residues of the α -helix in position -1, 3, and 6 with the 3', middle, and 5' nucleotide of a 3 bp DNA subsite, respectively. Positions 1, 2 and 5 have been shown to make direct or water-mediated contacts with the phosphate backbone of the DNA. Leucine is usually found in position 4 and packs into the hydrophobic core of the domain. Position 2 of the α -helix has been shown to interact with other helix residues and, in addition, can make contact to a nucleotide outside the 3 bp subsite [Pavletich et al., (1991) *Science* 252(5007), 809-817; Elrod-Erickson et al., (1996) *Structure* 4(10), 1171-1180; Isalan, M. et al., (1997) *Proc Natl Acad Sci U S A* 94(11), 5617-5621].

The selection of modular zinc finger domains recognizing each of the 5'-GNN-3'

DNA subsites with high specificity and affinity and their refinement by site-directed mutagenesis has been demonstrated. These modular domains can be assembled into zinc finger proteins recognizing extended 18 bp DNA sequences which are unique within the human or any other genome. In addition, these proteins function as transcription factors and are capable of altering gene expression when fused to regulatory domains and can even be made hormone-dependent by fusion to ligand-binding domains of nuclear hormone receptors. To allow the rapid construction of zinc finger-based transcription factors binding to any DNA sequence it is important to extend the existing set of modular zinc finger domains to recognize each of the 64 possible DNA triplets. This aim can be achieved by phage display selection and/or rational design.

Due to the limited structural data on zinc finger/DNA interaction rational design of zinc proteins is very time consuming and may not be possible in many instances. In addition, most naturally occurring zinc finger proteins consist of domains recognizing the 5'-GNN-3' type of DNA sequences. Only a few zinc finger domains binding to sequences of the 5'-ANN-3' type are found in naturally occurring proteins, like finger 5 (5'-AAA-3') of Gfi-1 [Zweidler-McKay et al., (1996) *Mol. Cell. Biol.* 16(8), 4024-4034], finger 3 (5'-AAT-3') of YY1 [Hyde-DeRuyscher, et al., (1995) *Nucleic Acids Res.* 23(21), 4457-4465], fingers 4 and 6 (5'-[A/G]TA-3') of CF2II [Gogos et al., (1996) *PNAS* 93, 2159-2164] and finger 2 (5'-AAG-3') of TTK [Fairall et al., (1993) *Nature (London)* 366(6454), 483-7]. However, in structural analysis of protein/DNA complexes by X-ray or NMR studies, interaction of the amino acid residue in position 6 of the α -helix with a nucleotide other than 5' guanine was never observed. Therefore, the most promising approach to identify novel zinc finger domains binding to DNA target sequences of the type 5'-ANN-3', 5'-CNN-3' or 5'-TNN-3' is selection via phage display. The limiting step for this approach is the construction of libraries that allow the specification of a 5' adenine, cytosine or thymine. Phage display selections have been based on Zif268 in which in which different fingers of this protein were randomized [Choo et al., (1994) *Proc. Natl. Acad. Sci. U. S.*

A. 91(23), 11168-72; Rebar et al., (1994) *Science (Washington, D. C., 1883-)* 263(5147), 671-3; Jamieson et al., (1994) *Biochemistry* 33, 5689-5695; Wu et al., (1995) *PNAS* 92, 344-348; Jamieson et al., (1996) *Proc Natl Acad Sci USA* 93, 12834-12839; Greisman et al., (1997) *Science* 275(5300), 657-661]. A set of 16 domains recognizing the 5'-GNN-3' type of DNA sequences has previously been reported from a library where finger 2 of C7, a derivative of Zif268 [United States Patent No. 6,140,081, the disclosure of which is incorporated herein by reference; Wu et al., (1995) *PNAS* 92, 344-348 Wu, 1995 #164], was randomized [Segal et al., (1999) *Proc Natl Acad Sci USA* 96(6), 2758-2763]. In such a strategy, selection is limited to domains recognizing 5'-GNN-3' or 5'-TNN-3' due to the Asp² of finger 3 making contact with the complementary base of a 5' guanine or thymine in the finger-2 subsite [Pavletich et al., (1991) *Science* 252(5007), 809-817; Elrod-Erickson et al., (1996) *Structure* 4(10), 1171-1180]. The limited modularity of zinc finger domains, which may in some cases recognize a nucleotide outside the 3 bp subsite, has been discussed intensively [Wolfe et al., (1999) *Annu. Rev. Biophys. Biomol. Struct.* 3, 183-212; Segal et al., (2000) *Curr Opin Chem Biol* 4(1), 34-39; Pabo et al., (2000) *J. Mol. Biol.* 301, 597-624; Choo et al., (2000) *Curr. opin. Struct. Biol.* 10, 411-416]. One approach to overcome the limitations imposed by target site overlap is the randomization of amino acid residues in two adjacent fingers [Jamieson et al., (1996) *Proc Natl Acad Sci USA* 93, 12834-12839; Isalan et al., (1998) *Biochemistry* 37(35), 12026-12033]. A second, but time consuming approach is the sequential selection of fingers 1 to 3 for a specific 9 bp target site which accounts for the individual structure and mode of DNA binding of each finger and its surrounding fingers [Greisman et al., (1997) *Science* 275(5300), 657-661; Wolfe et al., (1999) *J Mol Biol* 285(5), 1917-1934].

The present approach is based on the modularity of zinc finger domains that allows the rapid construction of zinc finger proteins by the scientific community and demonstrates that the concerns regarding limitation imposed by cross-subsite interactions only occurs in a limited number of cases. The present disclosure introduces a new strategy for selection

of zinc finger domains specifically recognizing the 5'-ANN-3' type of DNA sequences. Specific DNA-binding properties of these domains was evaluated by a multi-target ELISA against all sixteen 5'-ANN-3' triplets. These domains can be readily incorporated into polydactyl proteins containing various numbers of 5'-ANN-3' domains, each specifically recognizing extended 18 bp sequences. Furthermore, these domains were able to specifically alter gene expression when fused to regulatory domains. These results underline the feasibility of constructing polydactyl proteins from pre-defined building blocks. In addition, the domains characterized here greatly increase the number of DNA sequences that can be targeted with artificial transcription factors.

Brief Summary of the Invention

The present disclosure teaches the construction of a novel phage display library enabling the selection of zinc finger domains recognizing the 5'-ANN-3' type of DNA sequences. Such domains were isolated and showed exquisite binding specificity for the 3 bp target site for against which they were selected. These zinc finger domains were engrafted into 6-finger proteins which bound specifically to their 18 bp target site with affinities in the pM to lower nM range. When fused to regulatory domains, one artificial 6-finger protein containing five 5'-ANN-3' and one 5'-TNN-3' domain regulated a luciferase reporter gene under control of a minimal promoter containing the zinc finger-binding site and a TATA-box. In addition, 6-finger proteins assembled from 5'-ANN-3' and 5'-GNN-3' domains showed specific transcriptional regulation of the endogenous *erbB-2* and *erbB-3* genes, respectively. These results show that modular zinc finger domains can be selected binding to 3 bp target sites other than 5'-GNN-3' and that they are suitable as additional modules to create artificial transcription factors, thereby greatly increasing the number of sequences that can be targeted by DNA-binding proteins built from pre-defined zinc finger domains.

Thus, the present invention provides an isolated and purified polypeptide that

contains from 2 to 12 zinc finger-nucleotide binding peptides, at least one of which peptides contains a nucleotide binding region having the sequence of any of SEQ ID NO: 7-71 and 107-112. In a preferred embodiment, the polypeptide contains from 2 to 6 zinc finger-nucleotide binding peptides. Such a polypeptide binds to a nucleotide that contains the sequence 5'-(ANN)_n-3', wherein each N is A, C, G, or T and where n is 2 to 12. Preferably, each of the peptides binds to a different target nucleotide sequence. A polypeptide of this invention can be operatively linked to one or more transcription regulating factors such as a repressor or an activator.

Polynucleotides that encode the polypeptides, expression vectors containing the polynucleotides and cells transformed with expression vectors are also provided.

In a related aspect, the present invention provides a process of regulating expression of a nucleotide sequence that contains the sequence (5'-ANN)_n-3', where n is an integer from 2 to 12. The process includes the step of exposing the nucleotide sequence to an effective amount of a polypeptide of this invention under conditions in which the polypeptide binds to expression regulating sequences of the nucleotide. Thus, the sequence 5'-(ANN)_n-3' can be located in the transcribed region of the nucleotide sequence, a promotor region of the nucleotide sequence or within an expressed sequence tag. A polypeptide is preferably operatively linked to one or more transcription regulating factors.

Brief Description of the Drawings

Fig.1 shows, schematically, construction of the zinc finger phage display library. Solid arrows show interactions of the amino acid residues of the zinc finger helices with the nucleotides of their binding site as determined by x-ray crystallography of Zif 268 and dotted lines show proposed interactions.

Fig.2 shows amino acid sequences of finger-2 recognition helices from selected clones. For each DNA target site several single clones were sequenced after the sixth round of panning and the amino acid determined to evaluate the selection. The DNA

recognition subsite of finger 2 is shown on the left of each set, followed by the number of each occurrence. The position of the amino acid residue within the α -helix is shown at the top. Boxed sequences were studied in detail and represent the best binders of each set. Sequences marked with an asterisk were additional analyzed clones. ¹Clones with a Ser⁴ to Cys⁴ mutation in finger 3. ²Sequences determined after subcloning the zinc finger sequences from the DNA pool after the sixth round of selection into a modified pMAL-c2 vector. * Additional clones analyzed.

Fig. 3 (shown in 26 panels: 3a-3z) shows multitarget specificity assay to study DNA-binding properties of selected domains. At the top of each graph is the amino acid sequence of the finger-2 domain (positions -2 to 6 with respect to the helix start) of the 3-finger protein analyzed. Black bars represent binding to target oligonucleotides with different finger-2 subsites: AAA, AAC, AAG, AAT, ACA, ACC, ACG, ACT, AGA, AGC, AGT, ATA, ATC, ATG, and ATT. White bars represent binding to a set of oligonucleotides where the finger-2 subsite only differs in the 5' position, for example for the domain binding the 5'-AAA-3' subsite (Fig. 3a) AAA, CAA, GAA, or TAA to evaluate the 5' recognition. The height of each bar represents the relative affinity of the protein for each target, averaged over two independent experiments and normalized to the highest signal among the black or white bars. Error bars represent the deviation from the average. Proteins analyzed correspond to the boxed helix sequences from Fig. 2. *: Proteins containing a finger-2 domain which was generated by site-directed mutagenesis.

Fig. 4 (shown in 2 panels: A and B) shows the construction of six-finger proteins containing domains recognizing 5'-ANN-3' DNA sequences and ELISA analysis. A: The six-finger proteins pAart, pE2X, pE3Y and pE3Z were constructed using the Sp1C framework. Amino acid residues in position -1 to 6 of the α -recognition helix are given for each finger that was utilized. B: Proteins were expressed in *E. coli* as MBP fusion proteins. Specificity of binding was analyzed by measurement of the binding activity from crude lysates to immobilized biotinylated oligonucleotides (E2X, 5'-ACC GGA GAA ACC AGG

GGA-3' (SEQ ID NO: 72); E3Y, 5'-ATC GAG GCA AGA GCC ACC-3' (SEQ ID NO: 73); E3Z, 5'-GCC GCA GCA GCC ACC AAT-3' (SEQ ID NO: 74); Aart, 5'-ATG-TAG-AGA-AAA-ACC-AGG-3' (SEQ ID NO: 75)). Assays were performed in duplicates, bars representing the standard deviation. Black bars: pE2X; striped bars: pE3Y; Gray bars: pE3Y; white bars: pAart.

Fig.5 (shown in 2 panels: A and B) shows luciferase reporter assay results. HeLa cells were cotransfected with the indicated zinc finger expression plasmid (pcDNA as control) and a reporter plasmid containing a luciferase gene under the control of a minimal promoter with TATA-box and zinc finger- binding sites (A: 5 x Aart binding site; B: 6 x 2C7 binding sites). Luciferase activity in cell extracts was measured 48h after transfection. Each bar represents the mean value (+/- standard deviation) of duplicate measurements. Y-axis: light units divided by 10^3 . X-axis: constructs coding for zinc finger proteins transfected; control, reporter alone.

Fig.6 (shown in 2 panels: A and B) shows retrovirus-mediated gene targeting. A431 cells were infected with retrovirus encoding for pE2X (A) or pE3Y (B) fused to either the activation domain VP64 or repression domain KRAB, respectively. Three days later, intact cells were stained with the ErbB-1-specific mAb EGFR-1, the ErbB-2-specific mAb FSP77, or the ErbB-3 specific mAb SGP1 in combination with phycoerythrin-labeled secondary antibody. Dotted lines: control staining (primary antibody omitted); dashed lines: specific staining of mock-infected cells; dotted/dashed lines: cells expressing zinc finger protein-VP64 fusions; solid lines: cells expressing zinc finger protein-KRAB fusions.

Detailed Description of the Invention

I Zinc finger Polypeptides

The present invention provides isolated and purified polypeptides that contain from 2 to 12 nucleotide binding domain peptides derived from zinc finger proteins. The

nucleotide binding domain peptides are derived from the α -helical portion of the zinc finger proteins. Preferred such nucleotide binding domain peptides have the amino acid residue sequence of any of SEQ ID NOs: 7-71 or 107-112. Preferably, the peptide has the amino acid residue sequence of any of SEQ ID NOs: 46-70. More preferably, the peptide has the amino acid residue sequence of any of SEQ ID NOs: 10, 11, 17, 19, 21, 23-30, 32, 34-36, 42, 43 or 45. Each of the peptides is designed and made to specifically bind nucleotide target sequences corresponding to the formula 5'-ANN-3', where N is any nucleotide (i.e., A, C, G or T). Thus, a polypeptide of this invention binds to a nucleotide sequence 5'-(ANN)_n-3', where n is an integer from 2 to 12. Preferably, n is from 2 to 6.

A compound of this invention is an isolated zinc finger-nucleotide binding polypeptide that binds to a ANN nucleotide sequence and modulates the function of that nucleotide sequence. The polypeptide can enhance or suppress transcription of a gene, and can bind to DNA or RNA. A zinc finger-nucleotide binding polypeptide refers to a polypeptide which is a mutagenized form of a zinc finger protein or one produced through recombination. A polypeptide may be a hybrid which contains zinc finger domain(s) from one protein linked to zinc finger domain(s) of a second protein, for example. The domains may be wild type or mutagenized. A polypeptide includes a truncated form of a wild type zinc finger protein. Examples of zinc finger proteins from which a polypeptide can be produced include TFIIIA and zif268.

A zinc finger-nucleotide binding polypeptide of this invention comprises a unique heptamer (contiguous sequence of 7 amino acid residues) within the α -helical domain of the polypeptide, which heptameric sequence determines binding specificity to a target nucleotide. That heptameric sequence can be located anywhere within the α -helical domain but it is preferred that the heptamer extend from position -1 to position 6 as the residues are conventionally numbered in the art. A polypeptide of this invention can include any β -sheet and framework sequences known in the art to function as part of a zinc finger protein.

A large number of zinc finger-nucleotide binding polypeptides were made and tested for binding specificity against target nucleotides containing a ANN triplet.

The zinc finger-nucleotide binding polypeptide derivative can be derived or produced from a wild type zinc finger protein by truncation or expansion, or as a variant of the wild type-derived polypeptide by a process of site directed mutagenesis, or by a combination of the procedures. The term "truncated" refers to a zinc finger-nucleotide binding polypeptide that contains less than the full number of zinc fingers found in the native zinc finger binding protein or that has been deleted of non-desired sequences. For example, truncation of the zinc finger-nucleotide binding protein TFIIIA, which naturally contains nine zinc fingers, might be a polypeptide with only zinc fingers one through three. Expansion refers to a zinc finger polypeptide to which additional zinc finger modules have been added. For example, TFIIIA may be extended to 12 fingers by adding 3 zinc finger domains. In addition, a truncated zinc finger-nucleotide binding polypeptide may include zinc finger modules from more than one wild type polypeptide, thus resulting in a "hybrid" zinc finger-nucleotide binding polypeptide.

The term "mutagenized" refers to a zinc finger derived-nucleotide binding polypeptide that has been obtained by performing any of the known methods for accomplishing random or site-directed mutagenesis of the DNA encoding the protein. For instance, in TFIIIA, mutagenesis can be performed to replace nonconserved residues in one or more of the repeats of the consensus sequence. Truncated zinc finger-nucleotide binding proteins can also be mutagenized.

Examples of known zinc finger-nucleotide binding polypeptides that can be truncated, expanded, and/or mutagenized according to the present invention in order to inhibit the function of a nucleotide sequence containing a zinc finger-nucleotide binding motif includes TFIIIA and zif268. Other zinc finger-nucleotide binding proteins will be known to those of skill in the art.

A polypeptide of this invention can be made using a variety of standard techniques well known in the art. Phage display libraries of zinc finger proteins were created and selected under conditions that favored enrichment of sequence specific proteins. Zinc finger domains recognizing a number of sequences required refinement by site-directed mutagenesis that was guided by both phage selection data and structural information. Previously we reported the characterization of 16 zinc finger domains specifically recognizing each of the 5'-GNN-3' type of DNA sequences, that were isolated by phage display selections based on C7, a variant of the mouse transcription factor Zif268 and refined by site-directed mutagenesis [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763; Dreier et al., (2000) *J. Mol. Biol.* 303, 489-502]. The molecular interaction of Zif268 with its target DNA 5'-GCG TGG GCG-3' (SEQ ID NO: 76) has been characterized in great detail. In general, the specific DNA recognition of zinc finger domains of the Cys₂-His₂ type is mediated by the amino acid residues -1, 3, and 6 of each α -helix, although not in every case are all three residues contacting a DNA base. One dominant cross-subsite interaction has been observed from position 2 of the recognition helix. Asp² has been shown to stabilize the binding of zinc finger domains by directly contacting the complementary adenine or cytosine of the 5' thymine or guanine, respectively, of the following 3 bp subsite. These non-modular interactions have been described as target site overlap. In addition, other interactions of amino acids with nucleotides outside the 3 bp subsites creating extended binding sites have been reported [Pavletich et al., (1991) *Science* 252(5007), 809-817; Elrod-Erickson et al., (1996) *Structure* 4(10), 1171-1180; Isalan et al., (1997) *Proc Natl Acad Sci U S A* 94(11), 5617-5621].

Selection of the previously reported phage display library for zinc finger domains binding to 5' nucleotides other than guanine or thymine met with no success, due to the cross-subsite interaction from aspartate in position 2 of the finger-3 recognition helix RSD-E-LKR. To extend the availability of zinc finger domains for the construction of artificial

transcription factors, domains specifically recognizing the 5'-ANN-3' type of DNA sequences were selected. Other groups have described a sequential selection method which led to the characterization of domains recognizing four 5'-ANN-3' subsites, 5'-AAA-3', 5'-AAG-3', 5'-ACA-3', and 5'-ATA-3' [Greisman et al., (1997) *Science* 275(5300), 657-661; Wolfe et al., (1999) *J Mol Biol* 285(5), 1917-1934]. The present disclosure uses a different approach to select zinc finger domains recognizing such sites by eliminating the target site overlap. First, finger 3 of C7 (RSD-E-RKR) (SEQ ID NO: 3) binding to the subsite 5'-GCG-3' was exchanged with a domain which did not contain aspartate in position 2 (Fig.1). The helix TSG-N-LVR (SEQ ID NO: 6), previously characterized in finger 2 position to bind with high specificity to the triplet 5'-GAT-3', seemed a good candidate. This 3-finger protein (C7.GAT; Fig. 1), containing finger 1 and 2 of C7 and the 5'-GAT-3'-recognition helix in finger-3 position, was analyzed for DNA-binding specificity on targets with different finger-2 subsites by multi-target ELISA in comparison with the original C7 protein (C7.GCG). Both proteins bound to the 5'-TGG-3' subsite (note that C7.GCG binds also to 5'-GGG-3' due to the 5' specification of thymine or guanine by Asp² of finger 3 which has been reported earlier).

The recognition of the 5' nucleotide of the finger-2 subsite was evaluated using a mixture of all 16 5'-XNN-3' target sites (X = adenine, guanine, cytosine or thymine). Indeed, while the original C7. GCG protein specified a guanine or thymine in the 5' position of finger 2, C7.GAT did not specify a base, indicating that the cross-subsite interaction to the adenine complementary to the 5' thymine was abolished. A similar effect has previously been reported for variants of Zif268 where Asp² was replaced by Ala² by site-directed mutagenesis [Isalan et al., (1997) *Proc Natl Acad Sci U S A* 94(11), 5617-5621; Dreier et al., (2000) *J. Mol. Biol.* 303, 489-502]. The affinity of C7.GAT, measured by gel mobility shift analysis, was found to be relative low, about 400 nM compared to 0.5 nM for C7.GCG [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763], which may in part be due to the lack of the Asp² in finger 3.

Based on the 3-finger protein C7.GAT, a library was constructed in the phage display vector pComb3H [Barbas et al., (1991) *Proc. Natl. Acad. Sci. USA* 88, 7978-7982; Rader et al., (1997) *Curr. Opin. Biotechnol.* 8(4), 503-508]. Randomization involved positions -1, 1, 2, 3, 5, and 6 of the α -helix of finger 2 using a VNS codon doping strategy (V = adenine, cytosine or guanine, N = adenine, cytosine, guanine or thymine, S = cytosine or guanine). This allowed 24 possibilities for each randomized amino acid position, whereas the aromatic amino acids Trp, Phe, and Tyr, as well as stop codons, were excluded in this strategy. Because Leu is predominately found in position 4 of the recognition helices of zinc finger domains of the type Cys₂-His₂ this position was not randomized. After transformation of the library into ER2537 cells (New England Biolabs) the library contained 1.5×10^9 members. This exceeded the necessary library size by 60-fold and was sufficient to contain all amino acid combinations.

Six rounds of selection of zinc finger-displaying phage were performed binding to each of the sixteen 5'-GAT-ANN-GCG-3' biotinylated hairpin target oligonucleotides, respectively, in the presence of non-biotinylated competitor DNA. Stringency of the selection was increased in each round by decreasing the amount of biotinylated target oligonucleotide and increasing amounts of the competitor oligonucleotide mixtures. In the sixth round the target concentration was usually 18 nM, 5'-CNN-3', 5'-GNN-3', and 5'-TNN-3' competitor mixtures were in 5-fold excess for each oligonucleotide pool, respectively, and the specific 5'-ANN-3' mixture (excluding the target sequence) in 10-fold excess. Phage binding to the biotinylated target oligonucleotide was recovered by capture to streptavidin-coated magnetic beads.

Clones were usually analyzed after the sixth round of selection. The amino acid sequences of selected finger-2 helices were determined and generally showed good conservation in positions -1 and 3 (Fig. 2), consistent with previously observed amino acid residues in these positions [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763]. Position -1 was Gln when the 3' nucleotide was adenine, with the exception of

domains binding 5'-ACA-3' (SPA-D-LTN) (SEQ ID NO: 77) where a Ser was strongly selected. Triplets containing a 3' cytosine selected Asp¹ (exceptions were domains binding 5'-AGC-3' and 5'-ATC-3'), a 3' guanine Arg¹, and a 5' thymine Thr¹ and His¹. The recognition of a 3' thymine by His¹ has also been observed in finger 1 of TKK binding to 5'-GAT-3' (HIS-N-FCR) (SEQ ID NO: 78); [Fairall et al., (1993) *Nature (London)* 366(6454), 483-7]). For the recognition of a middle adenine, Asp and Thr were selected in position 3 of the recognition helix. For binding to a middle cytosine, an Asp³ or Thr³ was selected, for a middle guanine, His³ (an exception was recognition of 5'-AGT-3', which may have a different binding mechanism due to the unusual amino acid residue His¹) and for a middle thymine, Ser³ and Ala³. Note also that the domains binding to 5'-ANG-3' subsites contain Asp² which likely stabilizes the interaction of the 3-finger protein by contacting the complementary cytosine of the 5' guanine in the finger-1 subsite. Even though there was a predominant selection of Arg and Thr in position 5 of the recognition helices, positions 1, 2 and 5 were variable.

The most interesting observation was the selection of amino acid residues in position 6 of the α -helices that determines binding to the 5' nucleotide of a 3 bp subsite. In contrast to the recognition of a 5' guanine, where the direct base contact is achieved by Arg or Lys in position 6 of the helix, no direct interaction has been observed in protein/DNA complexes for any other nucleotide in the 5' position [Elrod-Erickson et al., (1996) *Structure* 4(10), 1171-1180; Pavletich et al., (1993) *Science (Washington, D. C., 1883-)* 261(5129), 1701-7; Kim et al., (1996) *Nat Struct Biol* 3(11), 940-945; Fairall et al., (1993) *Nature (London)* 366(6454), 483-7; Houbaviy et al., (1996) *Proc Natl Acad Sci U S A* 93(24), 13577-82; Wuttke et al., (1997) *J Mol Biol* 273(1), 183-206; Nolte et al., (1998) *Proc Natl Acad Sci U S A* 95(6), 2938-2943]. Selection of domains against finger-2 subsites of the type 5'-GNN-3' had previously generated domains containing only Arg⁶ which directly contacts the 5' guanine [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763]. However, unlike the results for 5'-GNN-3' zinc finger domains, selections of

the phage display library against finger-2 subsites of the type 5'-ANN-3' identified domains containing various amino acid residues: Ala⁶, Arg⁶, Asn⁶, Asp⁶, Gln⁶, Glu⁶, Thr⁶ or Val⁶ (Fig. 2). In addition, one domain recognizing 5'-TAG-3' was selected from this library with the amino acid sequence RED-N-LHT (Fig. 3z) (SEQ ID NO: 71). Thr⁶ is also present in finger 2 of Zif 268 (RSD-H-LTT) (SEQ ID NO: 79) binding 5'-TGG-3' for which no direct contact was observed in the Zif 268/DNA complex.

Finger-2 variants of C7.GAT were subcloned into bacterial expression vector as fusion with maltose-binding protein (MBP) and proteins were expressed by induction with 1 mM IPTG (proteins (p) are given the name of the finger-2 subsite against which they were selected). Proteins were tested by enzyme-linked immunosorbant assay (ELISA) against each of the 16 finger-2 subsites of the type 5'-GAT ANN GCG-3' to investigate their DNA-binding specificity (Fig. 3, black bars). In addition, the 5'-nucleotide recognition was analyzed by exposing zinc finger proteins to the specific target oligonucleotide and three subsites which differed only in the 5'-nucleotide of the middle triplet. For example, pAAA was tested on 5'-AAA-3', 5'-CAA-3', 5'-GAA-3', and 5'-TAA-3' subsites (Fig. 3, white bars). Many of the tested 3-finger proteins showed exquisite DNA-binding specificity for the finger-2 subsite against they were selected. Binding properties of domains which were boxed in Fig. 2 and are considered the most specific binders of each set are represented in the upper panel of Fig. 3, while additional domains tested (marked with an asterisk in Fig. 2) are summarized in the lower panel of Fig. 3. The exception were pAGC and pATC whose DNA binding was too weak to be detected by ELISA. The most promising helix for pAGC (DAS-H-LHT) (SEQ ID NO: 80) which contained the expected amino acid Asp¹ and His³ specifying a 3' cytosine and middle guanine, but also a Thr⁶ not selected in any other case for a 5' adenine, was analyzed without detectable DNA binding.

To analyze a larger set, the pool of coding sequences for pAGC was subcloned into the plasmid pMal after the sixth round of selection and 18 individual clones were tested for

DNA-binding specificity, of which none showed measurable DNA-binding in ELISA. In the case of pATC, two helices (RRS-S-CRK and RRS-A-CRR) (SEQ ID NOs: 80, 81) were selected containing a Leu⁴ to Cys⁴ mutation, for which no DNA binding was detectable. Rational design was applied to find domains binding to 5'-AGC-3' or 5'-ATC-3', since no proteins binding these finger-2 subsites were generated by phage display. Finger-2 mutants were constructed based on the recognition helices which were previously demonstrated to bind specifically to 5'-GGC-3' (ERS-K-LAR (SEQ ID NO: 82), DPG-H-LVR (SEQ ID NO: 83)) and 5'-GTC-3' (DPG-A-LVR) (SEQ ID NO: 84) [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763]. For pAGC two proteins were constructed (ERS-K-LRA (SEQ ID NO: 85), DPG-H-LRV (SEQ ID NO: 86)) by simply exchanging position 5 and 6 to a 5' adenine recognition motif RA or RV (Fig. 3a, 3b and 3i). DNA binding of these proteins was below detection level. In the case of pATC two finger-2 mutants containing a RV motif (Fig. 3b) were constructed (DPG-A-LRV (SEQ ID NO: 87), DPG-S-LRV (SEQ ID NO: 88)). Both proteins bound DNA with extremely low affinity regardless if position 3 was Ala or Ser.

Analysis of the 3-finger proteins on the sixteen finger-2 subsites by ELISA revealed that some finger-2 domains bound best to a target they were not selected against. First, the predominantly selected helix for 5'-AGA-3' was RSD-H-LTN (SEQ ID NO: 63), which in fact bound 5'-AGG-3' (Fig. 3r). This can be explained by the Arg in position -1. In addition, this protein showed a better discrimination of a 5' adenine compared to the predominantly selected helix pAGG (RSD-H-LAE (SEQ ID NO: 55); Fig. 3j). Second, a helix binding specifically to 5'-AAG-3' (RSD-N-LKN (SEQ ID NO: 61); Fig. 3p) was actually selected against 5'-AAC-3' (Fig. 2), and bound more specific to the finger-2 subsite 5'-AAG-3' than pAAG (RSD-T-LSN (SEQ ID NO: 48); Fig. 3c), which had been selected in the 5'-AAG-3' set. In addition, proteins directed to target sites of the type 5'-ANG-3' showed cross reactivity with all four target sites of the type 5'-ANG-3', except for pAGG (Fig. 3j and 3r). The recognition of a middle purine seems more restrictive than of a

middle pyrimidine, because also pAAG (RSD-N-LKN (SEQ ID NO: 61); Fig. 3p) had only moderate cross-reactivity.

In comparison, the proteins pACG (RTD-T-LRD (SEQ ID NO: 52); Fig. 3g) and pATG (RRD-A-LNV (SEQ ID NO: 58); Fig. 3m) show cross-reactivity with all 5'-ANG-3' subsites. The recognition of a middle pyrimidine has been reported to be difficult in previous studies for domains binding to 5'-GNG-3' DNA sequences [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763; Dreier et al., (2000) *J. Mol. Biol.* 303, 489-502]. To improve the recognition of the middle nucleotide, finger-2 mutants containing different amino acid residues in position 3 were generated by site-directed mutagenesis. Binding of pAAG (RSD-T-LSN (SEQ ID NO: 48), Fig. 3c) was more specific for a middle adenine after a Thr³ to Asn³ mutation (Fig. 3o). The binding to 5'-ATG-3' (SRD-A-LNV (SEQ ID NO: 58); Fig. 3m) was improved by a single amino acid exchange Ala³ to Gln³ (Fig. 3w), while a Thr³ to Asp³ or Gln³ mutation for pACG (RSD-T-LRD (SEQ ID NO: 52); Fig. 3g) abolished DNA binding. In addition, the recognition helix pAGT (HRT-T-LLN (SEQ ID NO: 56); Fig. 3k) showed cross-reactivity for the middle nucleotide which was reduced by a Leu⁵ to Thr⁵ substitution (Fig. 3s). Surprisingly, improved discrimination for the middle nucleotide was often associated with some loss of specificity for the recognition of the 5' adenine (compare Fig. 3o-3p, 3m-3w, 3k-3s).

Selection of zinc finger domains binding to subsites containing a 5' adenine or cytosine from the previously described finger-2 library based on the 3-finger protein C7 [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763] was not suitable for the selection of zinc-finger domains due to the limitation of aspartate in position 2 of finger 3 which makes a cross-subsite contact to the nucleotide complementary of the 5' position of the finger-2 subsite (Fig. 1). We eliminated this contact by exchanging finger 3 with a domain lacking Asp². Finger 2 of C7.GAT was randomized and a phage display library constructed. In most cases, novel 3-finger proteins were selected binding to finger-2 subsites of the type 5'-ANN-3'. For the subsites 5'-AGC-3' and 5'-ATC-3' no tight

binders were identified. This was not expected, because the domains binding to the subsite 5'-GGC-3' and 5'-GTC-3' previously selected from the C7-based phage display library showed excellent DNA-binding specificity and affinity of 40 nM to their target site [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763]. One simple explanation would be the limiting randomization strategy by the usage of VNS codons which do not include the aromatic amino acid residues. These were not included in the library, because for the domains binding to 5'-GNN-3' subsites no aromatic amino acid residues were selected, even though they were included in the randomization strategy [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763]. However, there have been zinc finger domains reported containing aromatic residues, like finger 2 of CFII2 (VKD-Y-LTK (SEQ ID NO: 89); [Gogos et al., (1996) *PNAS* 93, 2159-2164]), finger 1 of TFIIIA (KNW-K-LQA (SEQ ID NO: 90); [Wuttke et al., (1997) *J Mol Biol.* 273(1), 183-206]), finger 1 of TTK (HIS-N-ECR (SEQ ID NO: 78); [Fairall et al., (1993) *Nature (London)* 366(6454), 483-7]) and finger 2 of GLI (AQY-M-LVV (SEQ ID NO: 91); [Pavletich et al., (1993) *Science (Washington, D. C., 1883-)* 261(5129), 1701-7]). Aromatic amino acid residues might be important for the recognition of the subsites 5'-AGC-3' and 5'-ATC-3'.

In recent years it has become clear that the recognition helix of Cys₂-His₂ zinc finger domains can adopt different orientations relative to the DNA in order to achieve optimal binding [Pabo et al., (2000) *J. Mol. Biol.* 301, 597-624]. However, the orientation of the helix in this region may be partially restricted by the frequently observed interaction involving the zinc ion, His⁷, and the phosphate backbone. Furthermore, comparison of binding properties of interactions in protein/DNA complexes have led to the conclusion that the C- α atom of position 6 is usually $8.8 \pm 0.8 \text{ \AA}$ apart from the nearest heavy atom of the 5' nucleotide in the DNA subsite, which favors only the recognition of a 5' guanine by Arg⁶ or Lys⁶ [Pabo et al., (2000) *J. Mol. Biol.* 301, 597-624]. To date, no interaction of any other position 6 residue with a base other than guanine has been observed in protein/DNA complexes. For example, finger 4 of YY1 (QST-N-LKS) (SEQ ID NO: 92) recognizes 5'-

CAA-3' but there was no contact observed between Ser⁶ and the 5' cytosine [Houbaviy et al., (1996) *Proc Natl Acad Sci U S A* 93(24), 13577-82]. Further, in the case of Thr⁶ in finger 3 of YY1 (LDF-N-LRT) (SEQ ID NO: 93), recognizing 5'-ATT-3', and in finger 2 of Zif268 (RSD-H-LTT) (SEQ ID NO: 79), specifying 5'-T/GGG-3', no contact with the 5' nucleotide was observed [Houbaviy et al., (1996) *Proc Natl Acad Sci U S A* 93(24), 13577-82; Elrod-Erickson et al., (1996) *Structure* 4(10), 1171-1180]. Finally, Ala⁶ of finger 2 of tramtrack (RKD-N-MTA) (SEQ ID NO: 94) binding to the subsite 5'-AAG-3' does not contact the 5' adenine [Fairall et al., (1993) *Nature (London)* 366(6454), 483-7].

Amino acid residues Ala⁶, Val⁶, Asn⁶ and even Arg⁶, which in a different context was demonstrated to bind a 5' guanine efficiently [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763], were predominantly selected from the C7.GAT library for DNA subsites of the type 5'-ANN-3' (Fig. 2). In addition, position 6 was selected as Thr, Glu and Asp depending on the finger-2 target site. This is consistent with early studies from other groups where positions of adjacent fingers were randomized [Jamieson et al., (1996) *Proc Natl Acad Sci USA* 93, 12834-12839; Isalan et al., (1998) *Biochemistry* 37(35), 12026-12033]. Screening of phage display libraries had resulted in selection of amino acid residues Tyr, Val, Thr, Asn, Lys, Glu and Leu, as well as Gly, Ser and Arg, but not Ala, for the recognition of a 5' adenine. In addition, using a sequential phage display selection strategy several domains binding to 5'-ANN-3' subsites were identified and specificity evaluated by target site selections. Arg, Ala and Thr in position 6 of the helix were demonstrated to recognize predominantly a 5' adenine [Wolfe et al., (1999) *Annu. Rev. Biophys. Biomol. Struct.* 3, 183-212].

In addition, Thr⁶ specifies a 5' adenine as shown by target site selection for finger 5 of Gfi-1 (QSS-N-LIT) (SEQ ID NO: 95) binding to the subsite 5'-AAA-3' [Zweidler-McKay et al., (1996) *Mol. Cell. Biol.* 16(8), 4024-4034]. These examples, including the present results, indicate that there is likely a relation between amino acid residue in position 6 and the 5' adenine, because they are frequently selected. This is at odds with data from

crystallographic studies, that never showed interaction of position 6 of the α -helix with a 5' nucleotide except guanine. One simple explanation might be that short amino acid residues, like Ala, Val, Thr, or Asn are not a sterical hindrance in the binding mode of domains recognizing 5'-ANN-3' subsites. This is supported by results gathered by site-directed mutagenesis in position 6 for a helix (QRS-A-LTV) (SEQ ID NO: 96) binding to a 5'-G/ATA-3' subsite [Gogos et al., (1996) *PNAS* 93, 2159-2164]. Replacement of Val⁶ with Ala⁶, which were also found for domains described here, or Lys⁶, had no effect on the binding specificity or affinity.

Computer modeling was used to investigate possible interactions of the frequently selected Ala⁶, Asn⁶ and Arg⁶ with a 5' adenine. Analysis of the interaction from Ala⁶ in the helix binding to 5'-AAA-3' (QRA-N-LRA; Fig. 3a) (SEQ ID NO: 46) with a 5' adenine was based on the coordinates of the protein/DNA complex of finger 1 (QSG-S-LTR) (SEQ ID NO: 97) from a Zif268 variant. If Gln¹ and Asn³ of QRA-N-LRA (SEQ ID NO: 98) hydrogen bond with their respective adenine bases in the canonical way, these interactions should fix a distance of about 8 Å between the methyl group of Ala⁶ and the 5' adenine and more than 11 Å between the methyl groups of Ala⁶ and the thymine base-paired to the adenine, suggesting also that no direct contact can be proposed for Val⁶ and Thr⁶.

Interestingly, the expected lack of 5' specificity by short amino acids in position 6 of the α -helix is only partially supported by the binding data. Helices such as RRD-A-LNV (SEQ ID NO: 58) (Fig. 3m) and the finger-2 helix RSD-H-LTT (SEQ ID NO: 5) of C7.GAT did indeed show essentially no 5' specificity. However, helix DSG-N-LRV (SEQ ID NO: 47) (Fig. 3b) displayed excellent specificity for a 5' adenine, while TSH-G-LTT (SEQ ID NO: 70) (Fig. 3y) was specific for 5' adenine or guanine. Other helices with short position-6 residues displayed varying degrees of 5' specificity, with the only obvious consistency being that 5' thymine was usually excluded (Fig. 3). Since it is unlikely that the position-6 residue can make a direct contribution to specificity, the observed binding patterns must derive from another source. Possibilities include local sequence-specific

DNA structure and overlapping interactions from neighboring domains. The latter possibility is disfavored, however, because the residue in position 2 of finger 3 (which is frequently observed to contact the neighboring site) is glycine in the parental protein C7.GAT, and because 5' thymine was not excluded by the two helices mentioned above.

Asparagine was also frequently selected in position 6. Helix HRT-T-LTN (SEQ ID NO: 56) (Fig. 3k) and RSD-T-LSN (SEQ ID NO: 48) (Fig. 3c) displayed excellent specificity for 5' adenine. However, Asn⁶ also seemed to impart specificity for both adenine and guanine (Fig. 3n, 3p and 3r), suggesting an interaction with the N7 common to both nucleotides. Computer modeling of the helix binding to 5'-AGG-3' (RSD-H-LTN (SEQ ID NO: 90); Fig. 3r), based on the coordinates of finger 2, binding to 5'-TGG-3', in the Zif268/DNA crystal structure (RSD-H-LTT (SEQ ID NO: 79); [Elrod-Erickson et al., (1996) *Structure* 4(10), 1171-1180]), suggested that the N- δ of Asn⁶ would be approximately 4.5Å from N7 of the 5' adenine. A modest reorientation of the α -helix which is considered within the range of canonical docking orientations [Pabo et al., (2000) *J. Mol. Biol.* 301, 597-624], could plausibly bring the N- δ within hydrogen bonding distance, analogous to the reorientation observed when glutamate rather than arginine appears in position -1. However, it is interesting to speculate why Asn⁶ was selected in this 5'-ANN-3' recognition set while the longer Gln⁶ was not. Gln⁶, being more flexible, may have been able to stabilize other interactions that were selected against during phage display. Alternatively, the shorter side chain of Asn⁶ might accommodate an ordered water molecule that could contact the 5' nucleotide without reorientation of the helix.

The final residue to be considered is Arg⁶. It was somewhat surprising that Arg⁶ was selected so frequently on 5'-ANN-3' targets because in our previous studies, it was unanimously selected to recognize a 5' guanine with high specificity [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763]. However, in the current study, Arg⁶ primarily specified 5' adenine (Fig. 3e, f, h and v), in some cases in addition to recognition

of a 5' guanine (Fig. 3t and u). Computer modeling of helix binding to 5'-ACA-3' (SPA-D-LTR (SEQ ID NO: 50); Fig. 3e), based on the coordinates of finger 1 QSG-S-LTR (SEQ ID NO: 98) of a Zif 268 variant binding 5'-GCA-3' [Elrod-Erickson et al., (1998) *Structure* 6(4), 451-464], suggested that Arg⁶ could easily adopt a configuration that allowed it to make a cross-strand hydrogen bond to O4 of a thymine base-paired to 5' adenine. In fact, Arg⁶ could bind with good geometry to both the O4 of thymine and O6 of a guanine base-paired to a middle cytosine. Such an interaction is consistent with the fact that Arg⁶ was selected almost unanimously when the target sequence was 5'-ACN-3'. The expectation for arginine to facilitate multiple interactions is compelling. Several lysines in TFIIIA were observed by NMR to be conformationally flexible [Foster et al., (1997) *Nat. Struct. Biol.* 4(8), 605-608], and Gln¹ behaves in a manner which suggests flexibility [Dreier et al., (2000) *J. Mol. Biol.* 303, 489-502]. Arginine has more rotatable bonds and more hydrogen bonding potential than lysine or glutamine and it is attractive to speculate that Arg⁶ is not limited to recognition of 5' guanine.

Amino acid residues in positions -1 and 3 were generally selected in analogy to their 5'-GNN-3' counterparts with two exceptions. His⁻¹ was selected for pAGT and pATT, recognizing a 3' thymine (Fig. 3k, 3n and 3y), and Ser⁻¹ for pACA, recognizing a 3' adenine (Fig. 3e and 3t). While Gln⁻¹ was frequently used to specify a 3' adenine in subsites of the type 5'-GNN-3', a new element of 3' adenine recognition was suggested from this study involving Ser⁻¹ selected for domains recognizing the 5'-ACA-3' subsite (Fig. 2) which can make a hydrogen bond with the 3' adenine. Computer modeling demonstrates that Ala², co-selected in the helix SPA-D-LTR (SEQ ID NO: 50) (Fig. 3e), can potentially make a van der Waals contact with the methyl group of the thymine base-paired to 3' adenine. The best evidence that Ala² might be involved is that helix SPA-D-LTR (SEQ ID NO: 50) (Fig. 3e) is strongly specific for 3' adenine while SHS-D-LVR (SEQ ID NO: 65) (Fig. 3t) is not. Gln⁻¹ is often sufficient for 3' adenine recognition. However, data from our previous studies suggested that the side chain of Gln⁻¹ can adopt

multiple conformations, enabling, for example, recognition of 3' thymine [Nardelli et al., (1992) *Nucleic Acids Res.* 20(16), 4137-44; Elrod-Erickson et al., (1998) *Structure* 6(4), 451-464; Dreier et al., (2000) *J. Mol. Biol.* 303, 489-502]. Ala² in combination with Ser¹ may be an alternative means to specificity a 3' adenine.

Another interaction not observed in the 5'-GNN-3' study is the cooperative recognition of 3' thymine by His¹ and the residue at position 2. In finger 1 of the crystal structure of the tramtrack/DNA complex, helix HIS-N-FCR (SEQ ID NO: 99) binds the subsite 5'-GAT-3' [Fairall et al., (1993) *Nature (London)* 366(6454), 483-7]. The His¹ ring is perpendicular to the plane of the 3' thymine base and is approximately 4Å from the methyl group. Ser² additionally makes a hydrogen bond with O4 of 3' thymine. A similar set of contacts can be envisioned by computer modeling for the recognition of 5'-ATT-3' by helix HKN-A-LQN (SEQ ID NO: 100) (Fig. 3n). Asn² in this helix has the potential not only to hydrogen bond with 3' thymine but also with the adenine base-paired to thymine. His¹ was also found for the helix binding 5'-AGT-3' (HRT-T-LLN (SEQ ID NO: 98); Fig. 3k) in combination with a Thr². Thr is structurally similar to Ser and might be involved in a similar recognition mechanism.

In conclusion, the results of the characterization of zinc finger domains reported in this study binding 5'-ANN-3' DNA subsites is consistent with the overall view that there is no general recognition code, which makes rational design of additional domains difficult. However, phage display selections can be applied and pre-defined zinc finger domains can serve as modules for the construction of artificial transcription factors. The domains characterized here enables targeting of DNA sequences other than 5'-(GNN)₆-3'. This is an important supplement to existing domains, since G/C-rich sequences often contain binding sites for cellular proteins and 5'(GNN)₆-3' sequences may not be found in all promoters.

II. Polynucleotides, Expression Vectors and Transformed Cells

The invention includes a nucleotide sequence encoding a zinc finger-nucleotide binding polypeptide. DNA sequences encoding the zinc finger-nucleotide binding polypeptides of the invention, including native, truncated, and expanded polypeptides, can be obtained by several methods. For example, the DNA can be isolated using hybridization procedures which are well known in the art. These include, but are not limited to: (1) hybridization of probes to genomic or cDNA libraries to detect shared nucleotide sequences; (2) antibody screening of expression libraries to detect shared structural features; and (3) synthesis by the polymerase chain reaction (PCR). RNA sequences of the invention can be obtained by methods known in the art (See, for example, Current Protocols in Molecular Biology, Ausubel, et al. Eds., 1989).

The development of specific DNA sequences encoding zinc finger-nucleotide binding polypeptides of the invention can be obtained by: (1) isolation of a double-stranded DNA sequence from the genomic DNA; (2) chemical manufacture of a DNA sequence to provide the necessary codons for the polypeptide of interest; and (3) in vitro synthesis of a double-stranded DNA sequence by reverse transcription of mRNA isolated from a eukaryotic donor cell. In the latter case, a double-stranded DNA complement of mRNA is eventually formed which is generally referred to as cDNA. Of these three methods for developing specific DNA sequences for use in recombinant procedures, the isolation of genomic DNA is the least common. This is especially true when it is desirable to obtain the microbial expression of mammalian polypeptides due to the presence of introns.

For obtaining zinc finger derived-DNA binding polypeptides, the synthesis of DNA sequences is frequently the method of choice when the entire sequence of amino acid residues of the desired polypeptide product is known. When the entire sequence of amino acid residues of the desired polypeptide is not known, the direct synthesis of DNA sequences is not possible and the method of choice is the formation of cDNA sequences. Among the standard procedures for isolating cDNA sequences of interest is the formation of plasmid-carrying cDNA libraries which are derived from reverse transcription of mRNA

which is abundant in donor cells that have a high level of genetic expression. When used in combination with polymerase chain reaction technology, even rare expression products can be clones. In those cases where significant portions of the amino acid sequence of the polypeptide are known, the production of labeled single or double-stranded DNA or RNA probe sequences duplicating a sequence putatively present in the target cDNA may be employed in DNA/DNA hybridization procedures which are carried out on cloned copies of the cDNA which have been denatured into a single-stranded form (Jay, et al., *Nucleic Acid Research* 11:2325, 1983).

A polypeptide of this invention can be operatively linked to one or more functional peptides. Such functional peptides are well known in the art and can be a transcription regulating factor such as a repressor or activation domain or a peptide having other functions. Exemplary and preferred such functional peptides are nucleases, methylases, nuclear localization domains, and restriction enzymes such as endo- or ectonucleases (See, e.g., Chandrasegaran and Smith, *Biol. Chem.*, 380:841-848, 1999).

An exemplary repression domain peptide is the ERF repressor domain (ERD) (Sgouras, D. N., Athanasiou, M. A., Beal, G. J., Jr., Fisher, R. J., Blair, D. G. & Mavrothalassitis, G. J. (1995) *EMBO J.* 14, 4781-4793), defined by amino acids 473 to 530 of the ets2 repressor factor (ERF). This domain mediates the antagonistic effect of ERF on the activity of transcription factors of the ets family. A synthetic repressor is constructed by fusion of this domain to the N- or C-terminus of the zinc finger protein. A second repressor protein is prepared using the Krüppel-associated box (KRAB) domain (Margolin, J. F., Friedman, J. R., Meyer, W., K.-H., Vissing, H., Thiesen, H.-J. & Rauscher III, F. J. (1994) *Proc. Natl. Acad. Sci. USA* 91, 4509-4513). This repressor domain is commonly found at the N-terminus of zinc finger proteins and presumably exerts its repressive activity on TATA-dependent transcription in a distance- and orientation-independent manner (Pengue, G. & Lania, L. (1996) *Proc. Natl. Acad. Sci. USA* 93, 1015-1020), by interacting with the RING finger protein KAP-1 (Friedman, J. R., Fredericks, W. J., Jensen, D. E., Speicher, D.

W., Huang, X.-P., Neilson, E. G. & Rauscher III, F. J. (1996) *Genes & Dev.* 10, 2067-2078). We utilized the KRAB domain found between amino acids 1 and 97 of the zinc finger protein KOX1 (Margolin, J. F., Friedman, J. R., Meyer, W., K.-H., Vissing, H., Thiesen, H.-J. & Rauscher III, F. J. (1994) *Proc. Natl. Acad. Sci. USA* 91, 4509-4513). In this case an N-terminal fusion with a zinc-finger polypeptide is constructed. Finally, to explore the utility of histone deacetylation for repression, amino acids 1 to 36 of the Mad mSIN3 interaction domain (SID) are fused to the N-terminus of the zinc finger protein (Ayer, D. E., Laherty, C. D., Lawrence, Q. A., Armstrong, A. P. & Eisenman, R. N. (1996) *Mol. Cell. Biol.* 16, 5772-5781). This small domain is found at the N-terminus of the transcription factor Mad and is responsible for mediating its transcriptional repression by interacting with mSIN3, which in turn interacts the co-repressor N-CoR and with the histone deacetylase mRPD1 (Heinzel, T., Lavinsky, R. M., Mullen, T.-M., Söderström, M., Laherty, C. D., Torchia, J., Yang, W.-M., Brard, G., Ngo, S. D. & al., e. (1997) *Nature* 387, 43-46). To examine gene-specific activation, transcriptional activators are generated by fusing the zinc finger polypeptide to amino acids 413 to 489 of the herpes simplex virus VP16 protein (Sadowski, I., Ma, J., Triezenberg, S. & Ptashne, M. (1988) *Nature* 335, 563-564), or to an artificial tetrameric repeat of VP16's minimal activation domain, (Seipel, K., Georgiev, O. & Schaffner, W. (1992) *EMBO J.* 11, 4961-4968), termed VP64.

III. Pharmaceutical Compositions

In another aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a zinc finger-nucleotide binding polypeptide or a therapeutically effective amount of a nucleotide sequence that encodes a zinc finger-nucleotide binding polypeptide in combination with a pharmaceutically acceptable carrier.

As used herein, the terms "pharmaceutically acceptable", "physiologically tolerable" and grammatical variations thereof, as they refer to compositions, carriers,

diluents and reagents, are used interchangeable and represent that the materials are capable of administration to or upon a human without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like which would be to a degree that would prohibit administration of the composition.

The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art. Typically such compositions are prepared as sterile injectables either as liquid solutions or suspensions, aqueous or non-aqueous, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified.

The active ingredient can be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, as well as pH buffering agents and the like which enhance the effectiveness of the active ingredient.

The therapeutic pharmaceutical composition of the present invention can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

Physiologically tolerable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH

value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, propylene glycol, polyethylene glycol and other solutes. Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, organic esters such as ethyl oleate, and water-oil emulsions.

IV. Uses

In one embodiment, a method of the invention includes a process for modulating (inhibiting or suppressing) expression of a nucleotide sequence comprising a zinc finger-nucleotide binding motif, which method includes the step of contacting the zinc finger-nucleotide binding motif with an effective amount of a zinc finger-nucleotide binding polypeptide that binds to the motif. In the case where the nucleotide sequence is a promoter, the method includes inhibiting the transcriptional transactivation of a promoter containing a zinc finger-DNA binding motif. The term "inhibiting" refers to the suppression of the level of activation of transcription of a structural gene operably linked to a promoter, containing a zinc finger-nucleotide binding motif, for example. In addition, the zinc finger-nucleotide binding polypeptide derivative may bind a motif within a structural gene or within an RNA sequence.

The term "effective amount" includes that amount which results in the deactivation of a previously activated promoter or that amount which results in the inactivation of a promoter containing a zinc finger-nucleotide binding motif, or that amount which blocks transcription of a structural gene or translation of RNA. The amount of zinc finger derived-nucleotide binding polypeptide required is that amount necessary to either displace a native zinc finger-nucleotide binding protein in an existing protein/promoter complex, or that amount necessary to compete with the native zinc finger-nucleotide binding protein to form a complex with the promoter itself. Similarly, the amount required to block a

structural gene or RNA is that amount which binds to and blocks RNA polymerase from reading through on the gene or that amount which inhibits translation, respectively. Preferably, the method is performed intracellularly. By functionally inactivating a promoter or structural gene, transcription or translation is suppressed. Delivery of an effective amount of the inhibitory protein for binding to or "contacting" the cellular nucleotide sequence containing the zinc finger-nucleotide binding protein motif, can be accomplished by one of the mechanisms described herein, such as by retroviral vectors or liposomes, or other methods well known in the art.

The term "modulating" refers to the suppression, enhancement or induction of a function. For example, the zinc finger-nucleotide binding polypeptide of the invention may modulate a promoter sequence by binding to a motif within the promoter, thereby enhancing or suppressing transcription of a gene operatively linked to the promoter nucleotide sequence. Alternatively, modulation may include inhibition of transcription of a gene where the zinc finger-nucleotide binding polypeptide binds to the structural gene and blocks DNA dependent RNA polymerase from reading through the gene, thus inhibiting transcription of the gene. The structural gene may be a normal cellular gene or an oncogene, for example. Alternatively, modulation may include inhibition of translation of a transcript.

The promoter region of a gene includes the regulatory elements that typically lie 5' to a structural gene. If a gene is to be activated, proteins known as transcription factors attach to the promoter region of the gene. This assembly resembles an "on switch" by enabling an enzyme to transcribe a second genetic segment from DNA to RNA. In most cases the resulting RNA molecule serves as a template for synthesis of a specific protein; sometimes RNA itself is the final product.

The promoter region may be a normal cellular promoter or, for example, an onco-promoter. An onco-promoter is generally a virus-derived promoter. For example, the long terminal repeat (LTR) of retroviruses is a promoter region which may be a target for a zinc

finger binding polypeptide variant of the invention. Promoters from members of the Lentivirus group, which include such pathogens as human T-cell lymphotropic virus (HTLV) 1 and 2, or human immunodeficiency virus (HIV) 1 or 2, are examples of viral promoter regions which may be targeted for transcriptional modulation by a zinc finger binding polypeptide of the invention.

To investigate whether the domains described here specifically binding to 5'-ANN-3' DNA sequences are suitable for the construction of such artificial transcription factors, four 6-finger proteins were assembled containing various numbers of 5'-ANN-3' domains. For each of the 6-finger proteins two 3 finger-coding regions were generated by PCR overlap extension using the Sp1C framework [Beerli et al., (1998) *Proc Natl Acad Sci U S A* 95(25), 14628-14633]. These 3-finger proteins were then fused to create 6-finger proteins via restriction sites (Fig. 4a) and cloned into the bacterial expression vector pMal for analysis of DNA-binding specificity and affinity. First, the 6-finger protein pAart was constructed, designed to recognize the arbitrary 18 bp target site 5'-ATG-TAG-AGA-AAA-ACC-AGG-3', which was completely free of 5'-GNN-3' triplets. Secondly, three 6-finger proteins containing both, 5'-GNN-3' and 5'-ANN-3' domains, were constructed. The well characterized model of the *erbB-2* and *erbB-3* genes for which we have previously shown that regulation of the endogenous gene was specifically achieved by, respectively, the 6-finger protein pE2C or pE3, which bound to 5'-(GNN)₆-3' DNA sequences [Beerli et al., (2000) *Proc Natl Acad Sci U S A* 97(4), 1495-1500; Beerli et al., (2000) *J. Biol. Chem.* 275(42), 32617-32627] were chosen for study.

The 6-finger protein pE2X binding to the target site 5'-ACC GGA GAA ACC AGG GGA-3' (SEQ ID NO: 101) in position -168 to -151 in the 5' untranslated region (UTR) of the *erbB-2* gene was constructed (Fig. 4a). In addition, two proteins binding in the 5' UTR of the *erbB-3* gene were generated. The protein pE3Y bound to the target site 5'-ATC GAG GCA AGA GCC ACC-3' (SEQ ID NO: 102) in position -94 to -111 of the 5' UTR, pE3Z in position -79 to -61 recognizing 5'-GCC GCA GCA GCC ACC AAT-3' (SEQ ID

NO: 103) (Fig. 4a). The coding sequence for the four 6-finger proteins were then cloned into the bacterial expression vector pMal. Crude extracts containing the zinc finger-MBP fusion protein were tested for DNA binding in ELISA (Fig. 4b). All four proteins show exquisite binding specificity to their target DNA with no cross-reactivity to the other target sites tested. The affinities were determined in gel mobility shift assays with purified proteins. The protein Aart bound its DNA target site with an affinity of 7.5 pM, pE2X with an affinity of 15 nM, pE3Y of 8 nM and pE3Z of 2 nM, which is in the range of affinities we have observed for most 6-finger proteins analyzed so far.

To evaluate the potential for specific gene regulation, the protein-coding sequence for Aart was cloned into the vector pcDNA and fused to the VP64 activation domain, a tetrameric repeat of the minimal activation domain derived from the herpes simplex virus protein VP16 [Seipel et al., (1992) *EMBO J.* 11(13), 4961-4968; Beerli et al., (1998) *Proc Natl Acad Sci U S A* 95(25), 14628-14633]. HeLa cells were transiently co-transfected with the effector constructs coding either only for the zinc finger protein or as fusion with the VP64 domain, and a luciferase reporter plasmid under the control of a minimal promoter containing the zinc finger-binding site and a TATA-box. The Aart-binding site was present in five copies while a promoter used as control contained six 2C7-binding sites. The expression of luciferase was up-regulated 2000-fold by the pAart-VP64 fusion protein in comparison to the control containing no activation domain (Fig. 5a). Activation was specific since no regulation of the reporter containing 6 x 2C7-binding sites was observed (Fig. 5b). As additional control for specificity the 6-finger protein p2C7 [Wu et al., (1995) *PNAS* 92, 344-348] was also tested, which only activated luciferase expression when the promoter contained 6x2C7-binding sites (Fig. 5b), but not when the promoter contained the 5xAart-binding (Fig. 5a). The 3-finger proteins of each half site of pAart fused to VP64 were not capable of activating luciferase expression which is consistent with previous results [Beerli et al., (2000) *Proc Natl Acad Sci U S A* 97(4), 1495-1500; Beerli et al., (2000) *J. Biol. Chem.* 275(42), 32617-32627].

To investigate the ability of the 6-finger proteins pE2X, pE3Y and pE3Z to transcriptionally regulate the endogenous *erbB-2* and *erbB-3* genes, respectively, the coding sequences were subcloned into the retroviral vector pMX-IRES-GFP and fused to the VP64 activation or the KRAB repression domain of Kox-1 [Margolin et al., (1994) *Proc. Natl. Acad. Sci. USA* 91, 4509-4513; Beerli et al., (1998) *Proc Natl Acad Sci U S A* 95(25), 14628-14633]. Retrovirus was used to infect the human carcinoma cell line A431. Three days after infection cells were subjected to flow cytometry to analyze expression levels of ErbB-2 and ErbB-3 (Fig. 6). The infection efficiency was determined by measurement of GFP expression. All cell pools, with the exception of pE2X-VP64, were infected to more than 80%. To determine the expression levels of ErbB-2 and ErbB-3, cells were stained with specific antibodies, or a control antibody specific for ErbB-1. The fusion protein pE2X-VP64 was capable to up-regulate ErbB-2 expression but only in 50% of the cells which is likely to be due to the low infection efficiency. pE3Y showed specific up- and down-regulation when fused to VP64 or KRAB, respectively, which was as efficient as the previously reported pE3. The pE3Z fusion proteins did not alter gene expression of *erbB-3*, eventhough pE3Z had the highest affinity of the 3 generated proteins. The zinc finger domains described herein specifically recognizing 5'-ANN-3' DNA sequences greatly contribute to the number of 6-finger proteins that can now be constructed and DNA sequences that can be targeted by zinc finger-based transcription factors.

Example 1: *Construction of zinc finger library and selection via phage display*

Construction of the zinc finger library was based on the earlier described C7 protein ([Wu et al., (1995) *PNAS* 92, 344-348]; Fig 1). Finger 3 recognizing the 5'-GCG-3' subsite was replaced by a domain binding to a 5'-GAT-3' subsite [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763] via a overlap PCR strategy using a primer coding for finger 3 (5'-GAGGAAGTTTGCCACCAGTGGCAACCTG

GTGAGGCATACCAAAATC-3') (SEQ ID NO: 104) and a pMal-specific primer (5'-GTAAAACGACGGCCAG TGCCAAGC-3') (SEQ ID NO: 105). Randomization the zinc finger library by PCR overlap extension was essentially as described [Wu et al., (1995) *PNAS* 92, 344-348; Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763]. The library was ligated into the phagemid vector pComb3H [Rader et al., (1997) *Curr. Opin. Biotechnol.* 8(4), 503-508]. Growth and precipitation of phage were performed as previously described [Barbas et al., (1991) *Methods: Companion Methods Enzymol.* 2(2), 119-124; Barbas et al., (1991) *Proc. Natl. Acad. Sci. USA* 88, 7978-7982; Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763]. Binding reactions were performed in a volume of 500 μ l zinc buffer A (ZBA: 10 mM Tris, pH 7.5/90 mM KCl/1m M $MgCl_2$ /90 μ M $ZnCl_2$)/0.2% BSA/5 mM DTT/1% Blotto (Biorad)/20 μ g double-stranded, sheared herring sperm DNA containing 100 μ l precipitated phage (10^{13} colony-forming units). Phage were allowed to bind to non-biotinylated competitor oligonucleotides for 1 hr at 4°C before the biotinylated target oligonucleotide was added. Binding continued overnight at 4°C. After incubation with 50 μ l streptavidin coated magnetic beads (Dyna; blocked with 5% Blotto in ZBA) for 1 hr, beads were washed ten times with 500 μ l ZBA/2% Tween 20/5 mM DTT, and once with buffer containing no Tween. Elution of bound phage was performed by incubation in 25 μ l trypsin (10 μ g/ml) in TBS (Tris-buffered saline) for 30 min at room temperature. Hairpin competitor oligonucleotides had the sequence 5'-GGCCGCN'N'N'ATC GAGTTTTCTCGATNNNGCGGCC-3' (SEQ ID NO: 106) (target oligonucleotides were biotinylated), where NNN represents the finger-2 subsite oligonucleotides, N'N'N' its complementary bases. Target oligonucleotides were usually added at 72 nM in the first three rounds of selection, then decreased to 36 nM and 18 nM in the sixth and last round. As competitor a 5'-TGG-3' finger-2 subsite oligonucleotide was used to compete with the parental clone. An equimolar mixture of 15 finger-2 5'-ANN-3' subsites, except for the target site, respectively, and competitor mixtures of each finger-2

subsites of the type 5'-CNN-3', 5'-GNN-3', and 5'-TNN-3' were added in increasing amounts with each successive round of selection. Usually no specific 5'-ANN-3' competitor mix was added in the first round.

Multitarget Specificity Assay and Gel mobility shift analysis - The zinc finger-coding sequence was subcloned from pComb3H into a modified bacterial expression vector pMal-c2 (New England Biolabs). After transformation into XL1-Blue (Stratagene) the zinc finger-maltose-binding protein (MBP) fusions were expressed after addition of 1 nM isopropyl β -D-thiogalactoside (IPTG). Freeze/thaw extracts of these bacterial cultures were applied in 1:2 dilutions to 96-well plates coated with streptavidin (Pierce), and were tested for DNA-binding specificity against each of the sixteen 5'-GAT ANN GCG-3' target sites, respectively. ELISA (enzyme-linked immunosorbant assay) was performed essentially as described [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763; Dreier et al., (2000) *J. Mol. Biol.* 303, 489-502]. After incubation with a mouse anti-MBP (maltose-binding protein) antibody (Sigma, 1:1000), a goat anti-mouse antibody coupled with alkaline phosphatase (Sigma, 1:1000) was applied. Detection followed by addition of alkaline phosphatase substrate (Sigma), and the OD405 was determined with SOFTMAX2.35 (Molecular Devices).

Gelshift analysis was performed with purified protein (Protein Fusion and Purification System, New England Biolabs) essentially as described.

Example 2: *Site-directed mutagenesis of finger 2*

Finger-2 mutants were constructed by PCR as described [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763; Dreier et al., (2000) *J. Mol. Biol.* 303, 489-502]. As PCR template the library clone containing 5'-TGG-3' finger 2 and 5'-GAT-3' finger 3 was used. PCR products containing a mutagenized finger 2 and 5'-GAT-3' finger 3 were

subcloned via NsiI and SpeI restriction sites in frame with finger 1 of C7 into a modified pMal-c2 vector (New England Biolabs).

Construction of polydactyl zinc finger proteins - Three-finger proteins were constructed by finger-2 stitchery using the SP1C framework as described [Beerli et al., (1998) *Proc Natl Acad Sci U S A* 95(25), 14628-14633]. The proteins generated in this work contained helices recognizing 5'-GNN-3' DNA sequences [Segal et al., (1999) *Proc Natl Acad Sci U S A* 96(6), 2758-2763], as well as 5'-ANN-3' and 5'-TAG-3' helices described here. Six finger proteins were assembled via compatible XmaI and BsrFI restriction sites. Analysis of DNA-binding properties were performed from IPTG-induced freeze/thaw bacterial extracts. For the analysis of capability of these proteins to regulate gene expression they were fused to the activation domain VP64 or repression domain KRAB of Kox-1 as described earlier ([Beerli et al., (1998) *Proc Natl Acad Sci U S A* 95(25), 14628-14633; Beerli et al., (2000) *Proc Natl Acad Sci U S A* 97(4), 1495-1500; Beerli et al., (2000) *J. Biol. Chem.* 275(42), 32617-32627]; VP64: tetrameric repeat of herpes simplex virus' VP16 minimal activation domain) and subcloned into pcDNA3 or the retroviral pMX-IRES-GFP vector ([Liu et al., (1997) *Proc. Natl. Acad. Sci. USA* 94, 10669-10674]; IRES, internal ribosome-entry site; GFP, green fluorescent protein).

Example 3: *General Methods*

Transfection and luciferase assays

HeLa cells were used at a confluency of 40-60%. Cells were transfected with 160 ng reporter plasmid (pGL3-promoter constructs) and 40 ng of effector plasmid (zinc finger-effector domain fusions in pcDNA3) in 24 well plates. Cell extracts were prepared 48 hrs after transfection and measured with luciferase assay reagent (Promega) in a MicroLumat LB96P luminometer (EG & Berthold, Gaithersburg, MD).

Retroviral gene targeting and Flow cytometric analysis

These assays were performed as described [Beerli et al., (2000) *Proc Natl Acad Sci USA* 97(4), 1495-1500; Beerli et al., (2000) *J. Biol. Chem.* 275(42), 32617-32627]. As primary antibody an ErbB-1-specific mAb EGFR (Santa Cruz), ErbB-2-specific mAb FSP77 (gift from Nancy E. Hynes; Harwerth et al., 1992) and an ErbB-3-specific mAb SGP1 (Oncogene Research Products) were used. Fluorescently labeled donkey F(ab')₂ anti-mouse IgG was used as secondary antibody (Jackson Immuno-Research).

Computer modeling

Computer models were generated using InsightII (Molecular Simulations, Inc.). Models were based on the coordinates of the co-crystal structures of Zif268-DNA (PDB accession 1AAY) and QGSR-GCAC (SEQ ID NO: 107) (1A1H). The structures were not energy minimized and are presented only to suggest possible interactions. Hydrogen bonds were considered plausible when the distance between the heavy atoms was 3(+/- 0.3) Å and the angle formed by the heavy atoms and hydrogen was 120° or greater. Plausible van der Waals interactions required a distance between methyl group carbon atoms of 4(+/- 0.3) Å.

WHAT IS CLAIMED IS:

1. A polypeptide comprising from 2 to 12 zinc finger-nucleotide binding peptides at least one of which peptides contains a nucleotide binding region having the sequence of any of SEQ ID NO: 7-70 and 107-112.
2. The polypeptide of claim 1 containing from 2 to 6 zinc finger-nucleotide binding peptides.
3. The polypeptide of claim 1 wherein each of the peptides binds to a different target nucleotide sequence.
4. The polypeptide of claim 2 that binds to a nucleotide that contains the sequence 5'-(ANN)_n-3', wherein each N is A, C, G, or T and where n is 2 to 6.
5. The polypeptide of claim 1 further operatively linked to one or more transcription regulating factors.
6. The polypeptide of claim 1 wherein each of the peptides contains a nucleotide binding region having the sequence of any of SEQ ID NO: 46-70.
7. The polypeptide of claim 1 wherein each of the peptides contains a nucleotide binding region having the sequence of any of SEQ ID NO: 7-45.
8. The polypeptide of claim 1 wherein each of the peptides contains a nucleotide binding region having the sequence of any of SEQ ID NO: 10, 11, 17, 19, 21, 23-30, 32, 34-36, 42, 43 or 45.

9. An isolated and purified polynucleotide that encodes the polypeptide of claim 1.
10. An expression vector containing the polynucleotide of claim 6.
11. A process of regulating expression of a nucleotide sequence that contains the sequence $(5'-ANN)_n-3'$, where n is an integer from 2 to 12, the process comprising exposing the nucleotide sequence to an effective amount of the polypeptide of claim 1.
12. The process of claim 10 wherein the sequence $5'-(ANN)_n-3'$ is located in the transcribed region of the nucleotide sequence.
13. The process of claim 10 wherein the sequence $5'-(ANN)_n-3'$ is located in a promotor region of the nucleotide sequence.
14. The process of claim 10 wherein the sequence $5'-(ANN)_n-3'$ is located within an expressed sequence tag.
15. The process of claim 10 wherein the polypeptide is operatively linked to one or more transcription regulating factors.




FIG. 1

Number in parenthesis = SEQ ID NO

AAA'
 -2-1 1 2 3 4 5 6
 1 S T N T K L H A (7)
 1 S S D R R T L R R (8)
 2 S T K E R L K T (9)
 1 S Q R A N L R A (10)

AAC

-2-1 1 2 3 4 5 6
 2 * S R K D N L K N (20)
 1 S D S G N L R V (21)
 1 S D R R N L R R (22)

AAG

-2-1 1 2 3 4 5 6
 3 S R S D T L S N (30)
 3 S R M G N L I R (31)

AAT

-2-1 1 2 3 4 5 6
 1 S T T G N L T V (36)
 1 * S T S G N L L V (37)
 1 S T L T I L K N (38)
 1 S R M S T L R H (39)

ACA'
 -2-1 1 2 3 4 5 6
 2 S S P A D L T R (11)
 1 * S S H S D L V R (12)
 1 * S N G G E L I R (13)
 1 S H Q L I L L K (14)
 1 S S R M D L K R (15)

ACC

-2-1 1 2 3 4 5 6
 4 S D K K D L T R (23)

ACG

-2-1 1 2 3 4 5 6
 3 S R T D T L R (32)
 3 * S R A H D L V R (33)

ACT

-2-1 1 2 3 4 5 6
 2 S T R T D L L R (40)
 1 * S T K T D L K R (41)
 1 S T H I D L I R (42)

AGA
 -2-1 1 2 3 4 5 6
 4 * S R S D H L T N (16)
 1 S Q L A H L R A (17)

AGC

-2-1 1 2 3 4 5 6
 1 * S D A S H L H T (24)
 1 S T N T G L K N (25)
 1 S T R M S L S T (26)
 1 S N H D A L R A (27)

AGG

-2-1 1 2 3 4 5 6
 3 S R S D H L A E (34)

AGT

-2-1 1 2 3 4 5 6
 4 S H R T T L L N (43)

ATA
 -2-1 1 2 3 4 5 6
 3 * S Q A S S L K A (18)
 1 S Q K S S L I A (19)

ATC

-2-1 1 2 3 4 5 6
 2 * S R R S A C R R (28)
 2 * S R R S S C R K (29)

ATG

-2-1 1 2 3 4 5 6
 4 S R R D A L N V (35)

ATT

-2-1 1 2 3 4 5 6
 3 * S T S H G L T T (44)
 1 S H K N A L Q N (45)

FIG. 2

Number in parenthesis = SEQ ID NO




FIG. 3a




FIG. 3b




FIG. 3c




FIG. 3d




FIG. 3e




FIG. 3f




FIG. 3g




FIG. 3h

Number in parenthesis = SEQ ID NO




FIG. 3i




FIG. 3j




FIG. 3k




FIG. 3l




FIG. 3m




FIG. 3n




FIG. 3o




FIG. 3p

5/9

Number in parenthesis = SEQ ID NO




FIG. 3q




FIG. 3r




FIG. 3s




FIG. 3t




FIG. 3u




FIG. 3v




FIG. 3w




FIG. 3x




FIG. 3y




FIG. 3z

Number in parenthesis = SEQ ID NO

P	F 1	F 2	F 3	F 4	F 5	F 6
Aart	RRD-A-LNV (58)	RED-N-LHT (71)	QLA-H-LRA (54)	QRA-N-LRA (46)	DKK-D-LTR (51)	RSD-H-LAE (55)
	3'-GTA-5'	3'-GAT-5'	3'-AGA-5'	3'-AAA-5'	3'-CCA-5'	3'-GGA-5'
E2X	DKK-D-LTR (51)	QSS-H-LVR (107)	QSS-N-LVR (108)	DKK-D-LTR (51)	RSD-H-LTN (63)	QSS-H-LVR (107)
	3'-CCA-5'	3'-AGG-5'	3'-AAG-5'	3'-CCA-5'	3'-GGA-5'	3'-AGG-5'
E3Y	DPG-A-LRV (109)	RSD-N-LVR (110)	QSG-D-LRR (111)	QLA-H-LRA (54)	DCR-D-LAR (112)	DKK-D-LTR (51)
	3'-CTA-5'	3'-GAG-5'	3'-ACG-5'	3'-AGA-5'	3'-CCG-5'	3'-CCA-5'
E3Z	DCR-D-LAR (112)	QSG-D-LRR (111)	QSG-D-LRR (111)	DCR-D-LAR (112)	DKK-D-LTR (51)	TTG-N-LTV (49)
	3'-CCG-5'	3'-ACG-5'	3'-ACG-5'	3'-CCG-5'	3'-CCA-5'	3'-TAA-5'

FIG. 4A

7/9




FIG. 4B

8/9




FIG. 5A




FIG. 5B

9 / 9

FIG. 6A





FIG. 6B



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 August 2002 (29.08.2002)

PCT

(10) International Publication Number
WO 02/066640 A3

- (51) International Patent Classification⁷: **C12N 15/12, C07K 14/47**
- (21) International Application Number: **PCT/EP02/01862**
- (22) International Filing Date: 21 February 2002 (21.02.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/791,106 21 February 2001 (21.02.2001) US
- (71) Applicant (for all designated States except AT, US): **NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).**
- (71) Applicant (for AT only): **NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).**
- (71) Applicant (for all designated States except US): **THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US).**
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BARBAS, Carlos, F. [US/US]; 755 Pacific Surf Drive, Solana Beach, CA 92075 (US). DREIER, Birgit [DE/CH]; Loowiesenstrasse 15, CH-8106 Adlikon (CH).**
- (74) Agent: **BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).**
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).**
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
24 July 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/066640 A3

(54) Title: **ZINC FINGER BINDING DOMAINS FOR NUCLEOTIDE SEQUENCE ANN**

(57) Abstract: Polypeptides that contain from 2 to 12 zinc finger-nucleotide binding regions that bind to nucleotide sequences of the formula (ANN)₂₋₁₂ are provided. Polynucleotides that encode such polypeptides and methods of regulating gene expression with such polypeptides and polynucleotides are also provided.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/01862

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/12 C07K14/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, EPO-Internal, EMBASE, SEQUENCE SEARCH, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ZWEIDLER-MCKAY ET AL: "Gfi-1 encodes a nuclear zinc finger protein that binds DNA and functions as a transcriptional repressor" MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 16, no. 8, August 1996 (1996-08), pages 4024-4034, XP002122304 ISSN: 0270-7306 abstract figures 2,3 table 1 figures 7,9 --- -/--	1-5,7, 9-15

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Δ* document member of the same patent family

Date of the actual completion of the international search

4 February 2003

Date of mailing of the international search report

11.06.03

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Keller, Y

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 02/01862

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FAIRALL L ET AL: "The crystal structure of a two zinc-finger peptide reveals an extension to the rules for zinc-finger/DNA recognition" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, no. 366, 2 December 1993 (1993-12-02), pages 483-487, XP002075345 ISSN: 0028-0836 abstract page 483, column 2 figure 1	1-5,7, 9-15
Y	WO 95 19431 A (BARBAS CARLOS F III ;GOTTESFELD JOEL M (US); SCRIPPS RESEARCH INST) 20 July 1995 (1995-07-20) abstract page 67 -page 68	1-5,7, 9-15
Y	DREIER B ET AL: "Insights into the molecular recognition of the 5'-GNN-3' family of DNA sequences by zinc finger domains." JOURNAL OF MOLECULAR BIOLOGY. ENGLAND 3 NOV 2000, vol. 303, no. 4, 3 November 2000 (2000-11-03), pages 489-502, XP002229801 ISSN: 0022-2836 the whole document	1-5,7, 9-15
Y	US 6 140 081 A (BARBAS CARLOS F) 31 October 2000 (2000-10-31) the whole document	1-5,7, 9-15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 02/01862

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-5, 7, 9-15 all partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-5, 7, 9-15 all partially

a polypeptide comprising zinc finger binding peptides where one finger has the sequence ID No 7, said polypeptide binding to a nucleotide having the sequence 5' (ANN)_n 3' (2 ≤ n ≤ 6). Methods to regulate expression of a nucleotide sequence by exposing said sequence to the aforementioned polypeptide.

2. Claims: 1-15 all partially

Inventions 2-68 respectively a zinc finger having SEQ ID No 8-70, 107-112 comprised in a polypeptide. Said polypeptide comprising the zinc finger nucleotide binding peptide recognizes a nucleotide sequence 5' (ANN)_n 3' where n is 2 to 6. Methods of regulating the expression of a nucleotide by exposing said nucleotide to the aforementioned nucleotide.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/01862

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9519431	A	20-07-1995	AU 704601 B2	29-04-1999
			AU 1686595 A	01-08-1995
			CA 2181548 A1	20-07-1995
			EP 0770129 A1	02-05-1997
			FI 962879 A	17-09-1996
			JP 9508019 T	19-08-1997
			NO 962991 A	18-09-1996
			WO 9519431 A1	20-07-1995
			US 2003059767 A1	27-03-2003
			US 6242568 B1	05-06-2001
			US 6140466 A	31-10-2000
US 6140081	A	31-10-2000	AU 1037600 A	08-05-2000
			BR 9914599 A	13-11-2001
			CA 2347025 A1	27-04-2000
			CN 1330713 T	09-01-2002
			WO 0023464 A2	27-04-2000
			EP 1121381 A2	08-08-2001
			JP 2002527097 T	27-08-2002